デフォルト表紙
市場調査レポート
商品コード
1533590

次世代シーケンシングの市場規模、シェア、成長分析:製品・サービス別、技術別、エンドユーザー別、地域別 - 産業予測、2024年~2031年

Next Generation Sequencing Market Size, Share, Growth Analysis, By Product & Service, By Technology, By End User, By Region - Industry Forecast 2024-2031


出版日
発行
SkyQuest
ページ情報
英文 157 Pages
納期
3~5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.96円
次世代シーケンシングの市場規模、シェア、成長分析:製品・サービス別、技術別、エンドユーザー別、地域別 - 産業予測、2024年~2031年
出版日: 2024年08月05日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の次世代シーケンシングの市場規模は、2022年に78億2,000万米ドルとなり、2023年の92億7,000万米ドルから、2031年までには360億4,000万米ドルに成長し、予測期間(2024年~2031年)のCAGRは18.5%で成長する見通しです。

次世代シーケンシング(NGS)は、数百万から数十億のDNA鎖を同時にシーケンスするために大規模な並列性を利用する高度な技術です。ハイスループット・シーケンスと呼ばれることもあるNGSは、従来のサンガー・シーケンス法よりも大きな利点を提供します。フラグメントクローニング戦略に依存するサンガーシーケンスとは異なり、NGSは費用対効果、高精度、迅速な結果が特徴です。最小限のサンプル量でも正確な結果を得ることができます。その結果、NGSはバイオマーカー探索、がん研究、個別化医療、農業、動物実験などさまざまな分野で重要なツールとなっています。ゲノムシーケンスの応用は、COVID-19のような病気の広がりを理解することにも及んでいます。2020年3月に設立されたCOVID-19 Genomics U.K. Consortium(COG-U.K.)は、コロナウイルスゲノムを探索するために全ゲノムシーケンスを利用しています。このコンソーシアムには、Wellcome Sanger Institute、NHS、公衆衛生機関、および複数の学術機関の協力が含まれます。これらの組織の総力を結集して、ウイルスの進化と伝播パターンをマッピングし、介入策が病気の進行や治療戦略にどのような影響を与えるかについての理解を深めることを目的としています。

目次

イントロダクション

  • 調査の目的
  • 定義
  • 市場範囲

調査手法

  • 情報調達
  • 二次・一次情報源
  • 市場規模予測
  • 市場の前提条件と制限

エグゼクティブサマリー

  • 市場概要見通し
  • 供給需要動向分析
  • セグメント別機会分析

市場力学と見通し

  • 市場力学
    • 促進要因
    • 機会
    • 抑制要因
    • 課題
  • ポーターの分析

主要な市場の考察

  • 技術分析
  • 価格分析
  • バリューチェーン分析
  • 市場のエコシステム
  • スタートアップ分析
  • 特許分析
  • 顧客と購買基準の分析
  • 規制情勢
  • イノベーションマトリクス
  • 主要な投資分析
  • 主要な成功要因
  • 市場魅力度指数
  • 競合の程度

次世代シーケンシング市場:製品・サービス別

  • 市場概要
  • NGS消耗品
  • シーケンシングサービス
    • エクソーム・ターゲットリシーケンシングとカスタムパネル
    • RNAシークエンシング
    • DE NOVOシーケンシング
    • チップシーケンシング
    • 全ゲノム配列解析
    • メチル配列
    • その他のシーケンスサービス
  • プレシーケンス製品・サービス
    • ライブラリの準備・ターゲットエンリッチメント
    • 品質管理
  • NGSプラットフォーム
    • イルミナ
    • NovaSeqシステム
    • NextSeqシステム
    • MiSeqシステム
    • iSeq 100システム
    • MiniSeqシステム
    • サーモフィッシャーサイエンティフィック
    • オックスフォードナノポアテクノロジーズ
    • パシフィックバイオサイエンス
    • その他のNGSプラットフォーム
  • バイオインフォマティクス
    • NGSデータ解析サービス
    • NGSデータ解析ソフトウェアとワークベンチ
    • NGSストレージ、管理、クラウドコンピューティングソリューション
  • NGSプラットフォーム向けサービス

次世代シーケンシング市場:技術別

  • 市場概要
  • 合成による配列決定
  • イオン半導体シーケンシング
  • ナノポアシーケンシング
  • 単一分子リアルタイムシーケンシング
  • その他のシーケンシング技術

次世代シーケンシング市場:用途別

  • 市場概要
  • 診断
    • がん診断
    • 感染症診断
    • 生殖健康診断
    • その他の診断用途
  • 医薬品の発見と開発
    • 薬理ゲノム学
    • その他の医薬品の発見と開発の用途
  • 農業および動物調査
  • その他の用途

次世代シーケンシング市場:エンドユーザー別

  • 市場概要
  • 学術機関・研究センター
  • 製薬・バイオテクノロジー企業
  • 病院・診療所
  • 参照ラボ
  • その他のエンドユーザー

次世代シーケンシング市場規模:地域別

  • 市場概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • スペイン
    • フランス
    • 英国
    • その他欧州地域
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • ラテンアメリカ
    • ブラジル
    • その他ラテンアメリカ地域
  • 中東・アフリカ(MEA)
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ地域

競合情勢

  • 上位5社の比較
  • 主要企業の市場ポジショニング(2023年)
  • 主要な市場企業が採用した戦略
  • 市場における最近の活動
  • 主要企業の市場シェア(2023年)

主要企業プロファイル

  • Illumina Inc.(US)
  • Thermo Fisher Scientific Inc.(US)
  • PerkinElmer Inc.(US)
  • BGI Group(China)
  • Agilent Technologies Inc.(US)
  • Eurofins Scientific SE(Luxembourg)
  • Pacific Biosciences of California Inc.(US)
  • Oxford Nanopore Technologies(UK)
  • QIAGEN NV(Netherlands)
  • F. Hoffmann-La Roche AG(Switzerland)
  • GENEWIZ Inc.(US)
  • Psomagen, Inc.(South Korea)
  • 10x Genomics Inc.(US)
  • Takara Bio(Japan)
  • Zymo Research(US)
  • NuGen Technologies(US)
  • Hamilton Company(US)
  • Beckman Coulter(US)
  • Becton, Dickinson, and Company(US)
  • Lucigen Corporation(US)
  • Novogene Co., Ltd.(China)
目次
Product Code: SQMIG35D2046

Global Next Generation Sequencing Market size was valued at USD 7.82 billion in 2022 and is poised to grow from USD 9.27 billion in 2023 to USD 36.04 billion by 2031, growing at a CAGR of 18.5% in the forecast period (2024-2031).

Next-generation sequencing (NGS) is an advanced technique that utilizes massive parallelism to sequence millions or even billions of DNA strands simultaneously. Often referred to as high-throughput sequencing, NGS offers significant advantages over traditional Sanger sequencing methods. Unlike Sanger sequencing, which relies on fragment-cloning strategies, NGS is characterized by its cost-effectiveness, high accuracy, and rapid results. It is capable of delivering precise outcomes even with minimal sample quantities. As a result, NGS has become a critical tool in various fields, including biomarker discovery, cancer research, personalized medicine, agriculture, and animal studies. The application of genome sequencing extends to understanding the spread of diseases such as COVID-19. The COVID-19 Genomics U.K. Consortium (COG-U.K.), established in March 2020, utilizes whole-genome sequencing to explore the coronavirus genome. This consortium includes collaborations between the Wellcome Sanger Institute, the NHS, public health agencies, and several academic institutions. The collective efforts of these organizations aim to map the virus's evolution and transmission patterns, enhancing our understanding of how interventions impact disease progression and treatment strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Sequencing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Sequencing Market Segmental Analysis

The next generation sequencing market is segmented into Product and Service, Technology, Application, End User and region. Based on the Product & Service, the market is segmented into NGS Consumables, Sequencing Services (Exome & Targeted Resequencing and Custom Panels, RNA Sequencing, DE NOVO Sequencing, Chip Sequencing, Whole-genome sequencing, MethYl Sequencing, Other Sequencing Services), Pre-sequencing Products & Services (Library Preparation And Target Enrichment, Quality Control), NGS Platforms (Illumina [NovaSeq Systems, Nextseq Systems, Miseq Systems, iSeq 100 Systems, Miniseq Systems], Thermo Fisher Scientific, Oxford Nanopore Technologies, Pacific Biosciences, Other NGS Platforms), Bioinformatics (NGS Data Analysis Services, NGS Data Analysis Software and Workbenches, NGS Storage, Management, And Cloud Computing Solutions), Services for NGS Platforms. Based on the Technology, the market is segmented into Sequencing by Synthesis, Ion Semiconductor Sequencing, Nanopore Sequencing, Single-molecule Real-time Sequencing, and Other Sequencing Technologies. Based on Application, the market is segmented into Diagnostics (Cancer Diagnostics, Infectious Disease Diagnostics, Reproductive Health Diagnostics, Other Diagnostic Applications, Drug Discovery and Development (Pharmacogenomics, Other Drug Discovery and Development Applications), Agricultural and Animal Research, Other Applications. Based on the End-user, the market is segmented into Academic Institutes and Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, Reference Laboratories, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa.

Drivers of the Global Next Generation Sequencing Market

The development of new and innovative technologies has led to the rise of next-generation sequencing (NGS), which is characterized by its speed, portability, and user-friendliness. These advancements enable quicker and more precise analyses, with significantly reduced turnaround times. By leveraging these technological improvements, companies gain a competitive edge, leading to increased investments in research and development. This, in turn, drives market growth and enhances the overall investment in innovation. The introduction of NGS represents a major leap forward in sequencing technology, offering substantial benefits in terms of efficiency and accuracy. These enhancements facilitate more rapid and reliable data analysis, positioning firms at the forefront of the industry. As businesses capitalize on these advancements, they contribute to a surge in market activity and foster further innovation, reinforcing their market position and driving continued growth in the sector.

Restraints in the Global Next Generation Sequencing Market

Next-generation sequencing generates enormous volumes of data, leading to significant challenges related to data storage, management, and analysis. The sheer scale of data produced necessitates the use of advanced and specialized bioinformatics tools and expertise, which may not always be readily available within an organization. These requirements can affect research and development timelines, elevate operational costs throughout the development cycle, and potentially restrict market opportunities. As a result, organizations may face difficulties in efficiently handling and leveraging the vast amounts of data generated by NGS technologies.

Market Trends of the Global Next Generation Sequencing Market

Next-generation sequencing (NGS) is increasingly utilized in both high and low-throughput research due to its growing simplicity, decreasing costs, and enhanced bioinformatics support. The application of NGS-based testing systems is broadening across various clinical fields, including oncology, reproductive health, and genetics. Organizations and companies are continuously striving for improvements and advancements in NGS technologies. For instance, RNA-sequencing is evolving to address a wider array of scientific and clinical domains, reflecting the ongoing efforts to expand the capabilities and applications of NGS.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • Start-up Analysis
  • Patent Analysis
  • Customer & Buying Criteria Analysis
  • Regulatory Landscape
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Market Attractive Index
  • Degree of Competition

Next Generation Sequencing Market by Product & Service

  • Market Overview
  • NGS Consumables
  • Sequencing Services
    • Exome & Targeted Resequencing and Custom Panels
    • RNA Sequencing
    • DE NOVO Sequencing
    • Chip sequencing
    • Whole-genome sequencing
    • Methyl sequencing
    • Other sequencing services
  • Pre-Sequencing Products & Services
    • Library preparation and target enrichment
    • Quality control
  • NGS Platforms
    • Illumina
    • NovaSeq systems
    • NextSeq systems
    • MiSeq systems
    • iSeq 100 systems
    • MiniSeq systems
    • Thermo Fisher Scientific
    • Oxford Nanopore Technologies
    • Pacific Biosciences
    • Other NGS Platforms
  • Bioinformatics
    • NGS Data Analysis Services
    • NGS Data Analysis Software and Workbenches
    • NGS Storage, Management, And Cloud Computing Solutions
  • Services for NGS Platforms

Next Generation Sequencing Market by Technology

  • Market Overview
  • Sequencing by synthesis
  • Ion semiconductor sequencing
  • Nanopore sequencing
  • Single-molecule real-time sequencing
  • Other sequencing technologies

Next Generation Sequencing Market by Application

  • Market Overview
  • Diagnostics
    • Cancer diagnostics
    • Infectious disease diagnostics
    • Reproductive health diagnostics
    • Other diagnostic applications
  • Drug discovery and development
    • Pharmacogenomics
    • Other drug discovery and development applications
  • Agricultural and animal research
  • Other applications

Next Generation Sequencing Market by End user

  • Market Overview
  • Academic institutes and research centers
  • Pharmaceutical and biotechnology companies
  • Hospitals and clinics
  • Reference laboratories
  • Other end users

Next Generation Sequencing Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Illumina Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PerkinElmer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BGI Group (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agilent Technologies Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eurofins Scientific SE (Luxembourg)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pacific Biosciences of California Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oxford Nanopore Technologies (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QIAGEN NV (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GENEWIZ Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Psomagen, Inc. (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • 10x Genomics Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takara Bio (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zymo Research (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • NuGen Technologies (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hamilton Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Beckman Coulter (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Becton, Dickinson, and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lucigen Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novogene Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments